“휴온스 합병외 플랜B 없다"…배수진 친 송수영 대표 [인터뷰]

Huon's Global's merger of its R&D subsidiary reveals the structural fragility of holding company models in sustaining biotech innovation. The shareholder backlash exposes a critical industry tension: companies cannot finance endless R&D without adequate capital mechanisms, forcing a choice between sustained research and shareholder returns. This case will determine whether Korean biotech firms can solve their structural underfunding through consolidation.